Piper Sandler Maintains Neutral on Neogen, Lowers Price Target to $6.5
NEOGApril 14, 2025
Read more →Guggenheim Maintains Buy on Neogen, Lowers Price Target to $13
NEOGApril 10, 2025
Read more →Neogen Q3 Earnings Fall Short On Expectations, Cuts Guidance Amid Macro Headwinds And Tariff Concerns
NEOGNeogen Corporation reports lower-than-expected Q3 earnings, declines in revenue, and a CEO transition, lowering its full-year guidance for 2025.
April 9, 2025
Read more →Neogen CEO John Adent To Step Down, Will Continue To Serve Until Successor Is Appointed
NEOGApril 9, 2025
Read more →Neogen Expects FY2025 Sales Of Approximately $895M Vs. Prior Guidance Of $905M-$925M And Consensus Of $910.23M And Adjusted EBITDA Of Approximately $195M Vs. Prior Guidance Of $205M-$215M
NEOGApril 9, 2025
Read more →Neogen Q3 2025 Adj EPS $0.10 Misses $0.11 Estimate, Sales $220.98M Miss $224.88M Estimate
NEOGApril 9, 2025
Read more →Neogen's Earnings: A Preview
NEOGApril 8, 2025
Read more →Neogen Says National Labor Relations Board Has Withdrawn Its Unfair Labor Practices Claim Against Company
NEOGFebruary 18, 2025
Read more →NeoGenomics shares are trading higher following strong FY25 guidance.
NEOGJanuary 15, 2025
Read more →Neogen Files For Non-Timely 10-Q With U.S. SEC; Expects To Record An Impairment Charge Of $461.4M In Q2; Expects Form 10-Q Will Report Net Loss Of $456.3M For Qtr Ended Nov 30, 2024
NEOGJanuary 10, 2025
Read more →Neogen Corporation Sees Fy25 Revenue Of $905M-$925M Vs. $934.88M Estimate (Prior View: $925M-$955M)
NEOGJanuary 10, 2025
Read more →Neogen Q2 2025 Adj. EPS $0.11 Beats $0.10 Estimate, Sales $231.258M Beat $227.159M Estimate
NEOGJanuary 10, 2025
Read more →Guggenheim Initiates Coverage On Neogen with Buy Rating, Announces Price Target of $15
NEOGDecember 19, 2024
Read more →NEOGEN And FOCO Highlights Collaboration On Epigenetic Research Project
NEOGApril 29, 2022
Read more →